Malaria vaccine trials begin using 'chimpanzee virus'

Feb 01, 2008

Trials are underway, funded by the Wellcome Trust, for a new vaccine to combat the most deadly form of malaria. For the first time ever, researchers will use a virus found in chimpanzees to boost the efficacy of the vaccine. The trials will take place at the University of Oxford's Jenner Institute, led by its Director, Professor Adrian Hill.

Malaria, caused by Plasmodium parasites, is one of the world's deadliest killers, killing over a million people each year, mainly women and young children in Africa and SE Asia. The most deadly species , P. falciparum, is responsible for 80% of malaria infections and 90% of deaths. As yet, there is no vaccine against malaria. This is because, for much of their life-cycle, the parasites responsible for infection live inside cells, where they cannot be reached by antibodies.

"We urgently need a vaccine to help in the fight against this deadly killer," says Professor Hill, a Wellcome Trust Principal Research Fellow. "Malaria parasites are able to outwit our immune system by hiding out in the body's cells, however. Finding a way to generate enough immune cells and antibodies to identify and destroy the parasites will be the key to preventing infection."

The vaccine being developed and trialled by Professor Hill's team in collaboration with Okairòs uses the company’s genetically-modified chimpanzee adenovirus to produce the malaria antigen and to stimulate a response to the vaccine in the body. Adenoviruses appear to be particularly potent for increasing the immune response to the malaria vaccine. However, because human adenoviruses, which cause diseases including the common cold and gastroenteritis, are widespread, most people have developed some immunity towards them. Using a chimpanzee adenovirus ensures that a recipient is unlikely to have resistance to this component of the vaccine.

"Chimpanzees have their own set of adenoviruses which rarely infect humans, so we have not built up immunity to them," explains virologist Dr Sarah Gilbert at the Jenner Institute. "This is why we have chosen such a virus to form the backbone of the new vaccine."

Professor Hill's team is currently recruiting for more volunteers for the first trials, which are to assess the safety of the vaccine. Because the active component of the adenovirus is removed, however, there is no danger of transmission to the human of the original chimpanzee virus.

The trial will also be measuring the response of the immune system. The team hopes to generate a response from CD8+ T-cells (sometimes known as killer cells) that should kill the parasites when they enter the liver, where they multiply undetected. However, if the T-cells do not kill all of the parasites, any that escape from liver into the bloodstream will still be able to enter red blood cells and cause illness.

The group plans to test a second vaccine which would then target the parasites in the bloodstream and red blood cells.

“Our ultimate goal is a combination product which targets the parasite at both the liver stage and the blood stage,” says Professor Hill. “Few people still think that you can get really strong protection from malaria based on a single component.”

Over a dozen vaccines have now been made by scientists at the University of Oxford and taken into clinical trials, but this is the first vaccine to have also been manufactured within a UK university, according to Professor Hill.

Source: Wellcome Trust

Explore further: New treatment approved for rare form of hemophilia

add to favorites email to friend print save as pdf

Related Stories

US official: Auto safety agency under review

3 hours ago

Transportation officials are reviewing the "safety culture" of the U.S. agency that oversees auto recalls, a senior Obama administration official said Friday. The National Highway Traffic Safety Administration has been criticized ...

Out-of-patience investors sell off Amazon

3 hours ago

Amazon has long acted like an ideal customer on its own website: a freewheeling big spender with no worries about balancing a checkbook. Investors confident in founder and CEO Jeff Bezos' invest-and-expand ...

Ebola.com domain sold for big payout

4 hours ago

The owners of the website Ebola.com have scored a big payday with the outbreak of the epidemic, selling the domain for more than $200,000 in cash and stock.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

13 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0